Drug intelligence / Profile preview

birofen

Development stage: Preclinical
Lead developer: Renmin Hospital of Wuhan University
Modality: Small Molecules
Administration: Intranasal

Overview

Birofen is a pharmaceutical drug currently undergoing clinical investigation as a nasal spray for the treatment of various types of rhinitis. It is being evaluated both as a standalone therapy and in combination with nasal hormones. The specific mechanism of action for Birofen has not been disclosed in the available information.

Other names: 毕罗芬

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on birofen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on birofen.

Explore the full profile